跳到主要內容

Foundation Fighting Blindness Retinal Degeneration Fund 的 Form 4 申報

Opus Genetics, Inc.(IRD),2025/12/11 申報

申報編號
0002042266-25-000003
申報時間
2025/12/11 17:35 ET
交易日
2025/12/9
申報延遲
2 天
10b5-1 計畫
沒有勾選

這份申報列了 1 筆非衍生性交易。公開市場賣出合計 $860.0 萬。交易後 2 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Foundation Fighting Blindness Retinal Degeneration FundCIK 0002042266董事、其他:See Remarks
Foundation Fighting Blindness, Inc.CIK 0002042532董事、其他:See Remarks

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2025/12/9Common StockS賣出處分−4,000,000$2.15−$8,600,0005,492,171直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

這份申報的交易價格沒有引用附註。

備註

For purposes of Section 16 of the Exchange Act of 1934, as amended, the Reporting Persons may be deemed a director by deputization of Issuer by virtue of the fact that Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to serve on the board of directors of Issuer and Dr. Graves is the chair of the board of directors of RDF and a member of the board of directors of FFB and Dr. Bennett is a member of the board of directors of RDF. FFB is the sole member of RDF and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold.

看 SEC EDGAR 上的完整原文 (在新分頁開啟)